146 related articles for article (PubMed ID: 36137481)
1. S-values for radium-223 and absorbed doses estimates for
Silva CCO; da Silva AX; Braz D; Lima LFC; Segars WP; de Sá LV
Appl Radiat Isot; 2022 Nov; 189():110387. PubMed ID: 36137481
[TBL] [Abstract][Full Text] [Related]
2. Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Dizdarevic S; McCready R; Vinjamuri S
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):192-217. PubMed ID: 31471713
[TBL] [Abstract][Full Text] [Related]
3. The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates.
Jiang W; Ulmert D; Simons BW; Abou DS; Thorek DLJ
Nucl Med Biol; 2018; 62-63():1-8. PubMed ID: 29800797
[TBL] [Abstract][Full Text] [Related]
4. A cell-based dosimetry model for radium-223 dichloride therapy using bone micro-CT images and GATE simulations.
Pinto GM; Bonifacio DAB; de Sá LV; Lima LFC; Vieira IF; Lopes RT
Phys Med Biol; 2020 Feb; 65(4):045010. PubMed ID: 31935695
[TBL] [Abstract][Full Text] [Related]
5. Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases.
Ogawa K; Higashi T; Mishiro K; Wakabayashi H; Shiba K; Odani A; Kinuya S
Sci Rep; 2020 Jul; 10(1):11917. PubMed ID: 32681007
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the radiation absorbed dose produced by
Azorín-Vega E; Rojas-Calderón E; Ferro-Flores G; Aranda-Lara L; Jiménez-Mancilla N; Nava-Cabrera MA
Appl Radiat Isot; 2019 Apr; 146():66-71. PubMed ID: 30753987
[TBL] [Abstract][Full Text] [Related]
7. Detection and quantification of
Mínguez P; Gómez de Iturriaga A; Fernández IL; Rodeño E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):20-27. PubMed ID: 28645684
[TBL] [Abstract][Full Text] [Related]
8. Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy.
Bastiani I; McMahon SJ; Turner P; Redmond KM; McGarry CK; Cole A; O'Sullivan JM; Prise KM; Ainsbury L; Anderson R
Nucl Med Biol; 2022; 106-107():10-20. PubMed ID: 34968973
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
10. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
Larsson E; Ljungberg M; Martensson L; Nilsson R; Tennvall J; Strand SE; Jonsson BA
Med Phys; 2012 Jul; 39(7):4434-43. PubMed ID: 22830776
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
13. The importance of BMI in dosimetry of
Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
[TBL] [Abstract][Full Text] [Related]
14. Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223.
Rajon DA; Canter BS; Leung CN; Bäck TA; Fritton JC; Azzam EI; Howell RW
Int J Radiat Biol; 2021; 97(9):1217-1228. PubMed ID: 34232830
[TBL] [Abstract][Full Text] [Related]
15. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
16. Personalized dosimetry of
Carter LM; Ocampo Ramos JC; Kesner AL
Biomed Phys Eng Express; 2021 Aug; 7(5):. PubMed ID: 34271565
[No Abstract] [Full Text] [Related]
17. Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [
Lassmann M; Eberlein U
Front Med (Lausanne); 2022; 9():1057373. PubMed ID: 36687439
[TBL] [Abstract][Full Text] [Related]
18. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
19. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
20. [
Yang Y; Alencar LMR; Pijeira MSO; Batista BDS; França ARS; Rates ERD; Lima RC; Gemini-Piperni S; Santos-Oliveira R
Drug Deliv; 2022 Dec; 29(1):186-191. PubMed ID: 35191342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
